About: Serum neopterin levels in relation to mild and severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum neopterin levels in relation to mild and severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serum neopterin levels in relation to mild and severe COVID-19
Creator	Fuchs, Dietmar Nilsson, Staffan Andersson, Lars-Magnus Gisslen, Magnus Gostner, Johanna Robertson, Josefina
Source	MedRxiv
abstract	Background The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19. Methods We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care. Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion. Results We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value 42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had elevated neopterin concentrations (>9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L. In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine, indicating an increased tryptophan catabolism, were seen in the group with severe cases. Conclusions In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how it can be used in clinical praxis.
has issue date	2020-08-22(xsd:dateTime)
bibo:doi	10.1101/2020.08.19.20178178
has license	medrxiv
sha1sum (hex)	7fc261080d5494bd16cfe33c6527d464d64d504c
schema:url	https://doi.org/10.1101/2020.08.19.20178178
resource representing a document's title	Serum neopterin levels in relation to mild and severe COVID-19
resource representing a document's body	covid:7fc261080d5494bd16cfe33c6527d464d64d504c#body_text
is schema:about of	named entity 'relation' named entity 'COUNT' named entity 'word count' named entity 'IFN' named entity 'enzyme activity' named entity 'coronavirus' named entity 'SciLifeLab' named entity 'KYN' named entity 'KYN' named entity 'nmol/L' named entity 'creatinine' named entity 'medRxiv' named entity 'medRxiv' named entity 'COVID' named entity 'neopterin' named entity 'medRxiv' named entity 'fluorescence detector' named entity 'reverse-phase HPLC' named entity 'cytokine' named entity 'neopterin' named entity 'standard deviations' named entity 'COVID-19' named entity 'enzyme-linked immunosorbent assay' named entity 'enzyme' named entity 'neopterin' named entity 'metabolism' named entity 'coronaviruses' named entity 'neopterin' named entity 'medRxiv' named entity 'hepatitis' named entity 'neopterin' named entity 'medRxiv' named entity 'COVID-19' named entity 'CC-BY-NC-ND 4.0' named entity 'COVID' named entity 'neopterin' named entity 'medRxiv' named entity 'anti-proliferative' named entity 'neopterin' named entity 'serum' named entity 'KYN' named entity 'COVID' named entity 'dengue fever' named entity 'Chromatography' named entity 'SPD' named entity 'viral infections' named entity 'peer review' named entity 'serum' named entity 'informed consent' named entity 'neopterin' named entity 'neopterin' named entity 'Shimadzu' named entity 'monocytes' named entity 'COVID' named entity 'IFN' named entity 'renal insufficiency' named entity 'kynurenine' named entity 'KYN' named entity 'autosampler' named entity 'prognostic marker' named entity 'neopterin' named entity 'creatinine' named entity 'blood samples' named entity 'serum' named entity 'COVID-19' named entity 'reverse transcriptase polymerase chain reaction' named entity 'COVID-19' named entity 'prognosis' named entity 'KYN' named entity 'CC-BY-NC-ND 4.0' named entity 'SD 9' named entity 'COVID' named entity '5.8' named entity 'COVID-19' named entity 'serum' named entity 'SARS-CoV-2' named entity 'neopterin' named entity 'progressive disease' named entity 'Hennigsdorf' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software